bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2025-4-2-1136bekhterev-1244Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEW25 лет исследований эффективности и безопасности применения различных лекарственных форм налтрексона для лечения синдрома зависимости от опиоидов25 years of studies on the efficacy and safety of different formulations of naltrexone for the opioid use disorder treatmenthttps://orcid.org/0000-0002-0529-4525КрупицкийЕ. М.KrupitskyE. M.

Крупицкий Евгений Михайлович — д.м.н., профессор, заместитель директора по научной работе и руководитель Института Аддиктологии; директор Института фармакологии им. А.В. Вальдмана

192019, Санкт-Петербург, ул. Бехтерева, 3

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Evgeny M. Krupitsky   

Saint Petersburg

kruenator@gmail.comhttps://orcid.org/0000-0001-5811-9897БлохинаЕ. А.BlokhinaE. A.

Блохина Елена Андреевна — д.м.н., руководитель лаборатории клинической фармакологии аддиктивных состояний отдела психофармакологии Института фармакологии им. А.В. Вальдмана

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Elena A. Blokhina  

Saint Petersburg

blokhinaelena@gmail.comhttps://orcid.org/0000-0002-2529-9243ЯрославцеваТ. С.YaroslavtsevaT. S.

Ярославцева Татьяна Сергеевна — научный сотрудник лаборатории клинической фармакологии аддиктивных состояний отдела психофармакологии Института фармакологии им. А.В. Вальдмана

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Tatiana S. Yaroslavtseva   

Saint Petersburg

tatianayaroslavtseva@gmail.comhttps://orcid.org/0000-0002-3597-7482ЗвартауЭ. Э.ZvartauE. E.

Звартау Эдвин Эдуардович — д.м.н., профессор, заведующий кафедрой фармакологии

197022, Санкт-Петербург, ул. Льва Толстого, 6-8

Edwin E. Zvartau  

Saint Petersburg

zvartau@gmail.comНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева; Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияV.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; I.P. Pavlov First St. Petersburg State Medical UniversityRussian FederationПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияI.P. Pavlov First St. Petersburg State Medical UniversityRussian Federation202510012026594-22029Copyright © Крупицкий Е.М., Блохина Е.А., Ярославцева Т.С., Звартау Э.Э., 20262026Крупицкий Е.М., Блохина Е.А., Ярославцева Т.С., Звартау Э.Э.Krupitsky E.M., Blokhina E.A., Yaroslavtseva T.S., Zvartau E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/1244

В обзоре представлены результаты двойных слепых рандомизированных исследований применения различных лекарственных форм антагониста опиоидных рецепторов налтрексона (пероральной, имлантируемой, инъекционной) для стабилизации ремиссии и профилактики рецидива у больных с синдромом зависимости от опиоидов (СЗО), выполненных авторами в течение последней четверти века. По данным этих исследований, депо-формы налтрексона (имплантируемая и инъекционная) являются более эффективными, чем пероральная, и позволяют отчасти решить проблему приверженности терапии, возникающую при использовании пероральной лекарственной формы налтрексона. Имплантат налтрексона эффективнее перорального препарата улучшал результаты лечения СЗО, и за счёт этого — приверженность и результаты антиретровирусной терапии ВИЧ-инфекции у больных с зависимостью от опиоидов. Лекарственные формы налтрексона пролонгированного действия характеризуются высокой эффективностью, хорошей переносимостью и открывают новые перспективы в терапии опиоидной зависимости.

The article overviews the results of the studies of different formulations of opioid antagonist naltrexone (oral, injectable and implantable) for stabilization of remission and relapse prevention in patients with opioid dependence conducted by authors during the last twenty five years. Based on the results of these studies, long-acting sustained release formulations of naltrexone (injectable and implantable) are more effective than oral formulation and may solve the problem of poor adherence to oral naltrexone. Naltrexone implant is more effective that oral formulation for both relapse prevention and improving adherence to antiretroviral therapy in patients with opioid dependence. Depot formulations of naltrexone are effective, well tolerated and open a new perspective for the treatment of opioid dependence.

Синдром зависимости от опиоидовналтрексонпролонгированные лекарственные формыфармакотерапияВИЧ-инфекцияopioid dependencenaltrexoneextended release depot formulationspharmacotherapyHIVReferencesАнохина И.П. Основные биологические механизмы зависимости от психоактивных веществ. Вопросы наркологии. 2013;6:40-59.Anohina IP. Main biological mechanisms of psychoactive substance addiction. Voprosy narkologii. 2013;6:40-59. (In Russ.).Крупицкий Е.М., Блохина Е.А. Применение пролонгированных форм налтрексона для лечения зависимости от опиатов. Вопросы наркологии. 2010;4:32-43.Krupitsky EM, Blokhina EA. Use of prolonged-release forms of naltrexon for the treatment of opiate dependence. Voprosy narkologii. 2010;4:32-43. (In Russ.).Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58(8):755-61. https://doi.org/10.1001/archpsyc.58.8.755Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58(8):755-61. https://doi.org/10.1001/archpsyc.58.8.755Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-8. https://doi.org/10.1001/archpsyc.63.2.210Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-8. https://doi.org/10.1001/archpsyc.63.2.210Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006 Mar;30(3):480-90. https://doi.org/10.1111/j.1530-0277.2006.00052.xDunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006 Mar;30(3):480-90. https://doi.org/10.1111/j.1530-0277.2006.00052.xFishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction. 2008 Aug;103(8):1399-401. https://doi.org/10.1111/j.1360-0443.2008.02252.xFishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction. 2008 Aug;103(8):1399-401. https://doi.org/10.1111/j.1360-0443.2008.02252.xGuidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009.Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009.Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108-15. https://doi.org/10.1001/archgenpsychiatry.2009.130Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry. 2009;66(10):1108-15. https://doi.org/10.1001/archgenpsychiatry.2009.130Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-70. https://doi.org/10.31887/DCNS.2007.9.2/hkleberKleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455-70. https://doi.org/10.31887/DCNS.2007.9.2/hkleberKrupitsky E. Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification. Neuropsychiatry.2012;2(4):355-62.Krupitsky E. Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification. Neuropsychiatry.2012;2(4):355-62.Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry. 2010;23(3):210-4. https://doi.org/10.1097/YCO.0b013e3283386578Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry. 2010;23(3):210-4. https://doi.org/10.1097/YCO.0b013e3283386578Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, et al. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV. 2019;6(4):e221-e229. https://doi.org/10.1016/S2352-3018(18)30362-XKrupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, et al. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV. 2019;6(4):e221-e229. https://doi.org/10.1016/S2352-3018(18)30362-XKrupitsky EM, Burakov AM, Didenko TY, Romanova T, Grinenko NI, Slavina TY, Grinenko AY, Tcheremissine O. Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addictive Disorders and Their Treatment. 2002;1(1):29-33. https://doi.org/10.1097/00132576-200205000-00006Krupitsky EM, Burakov AM, Didenko TY, Romanova T, Grinenko NI, Slavina TY, Grinenko AY, Tcheremissine O. Effects of citalopram treatment of protracted withdrawal (syndrome of anhedonia) in patients with heroin addiction. Addictive Disorders and Their Treatment. 2002;1(1):29-33. https://doi.org/10.1097/00132576-200205000-00006Kruptisky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, Zvartau EE, Woody GE. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction. 2007;102(7):1164-5. https://doi.org/10.1111/j.1360-0443.2007.01817.xKruptisky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, Zvartau EE, Woody GE. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction. 2007;102(7):1164-5. https://doi.org/10.1111/j.1360-0443.2007.01817.xKrupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, et al. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. Drug Alcohol Depend. 2013;132(3):674-80. https://doi.org/10.1016/j.drugalcdep.2013.04.021Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Tsoy M, Wahlgren V, et al. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. Drug Alcohol Depend. 2013;132(3):674-80. https://doi.org/10.1016/j.drugalcdep.2013.04.021Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973-81. https://doi.org/10.1001/archgenpsychiatry.2012.1aKrupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973-81. https://doi.org/10.1001/archgenpsychiatry.2012.1aKrupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse. 2016;42(5):614-20. https://doi.org/10.1080/00952990.2016.1197231Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, et al. Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. Am J Drug Alcohol Abuse. 2016;42(5):614-20. https://doi.org/10.1080/00952990.2016.1197231Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004;26(4):285-94. https://doi.org/10.1016/j.jsat.2004.02.002Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat. 2004;26(4):285-94. https://doi.org/10.1016/j.jsat.2004.02.002Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006;31(4):319-28. https://doi.org/10.1016/j.jsat.2006.05.005Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat. 2006;31(4):319-28. https://doi.org/10.1016/j.jsat.2006.05.005Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-13. https://doi.org/10.1016/S0140-6736(11)60358-9Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-13. https://doi.org/10.1016/S0140-6736(11)60358-9Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628-37. https://doi.org/10.1111/add.12208Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628-37. https://doi.org/10.1111/add.12208Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009;194(6):541-6. https://doi.org/10.1192/bjp.bp.108.055319Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2009;194(6):541-6. https://doi.org/10.1192/bjp.bp.108.055319Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-18. https://doi.org/10.1016/S0140-6736(17)32812-XLee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-18. https://doi.org/10.1016/S0140-6736(17)32812-XNunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32(4):503-17. https://doi.org/10.1080/00952990600918973Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32(4):503-17. https://doi.org/10.1080/00952990600918973O'Brien C, Cornish JW. Naltrexone for probationers and parolees. J Subst Abuse Treat. 2006;31(2):107-11. https://doi.org/10.1016/j.jsat.2006.06.002O'Brien C, Cornish JW. Naltrexone for probationers and parolees. J Subst Abuse Treat. 2006;31(2):107-11. https://doi.org/10.1016/j.jsat.2006.06.002Opheim A, Benth JŠ, Solli KK, Kloster PS, Fadnes LT, Kunøe N, Gaulen Z, Tanum L. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemp Clin Trials. 2023;135:107360. https://doi.org/10.1016/j.cct.2023.107360Opheim A, Benth JŠ, Solli KK, Kloster PS, Fadnes LT, Kunøe N, Gaulen Z, Tanum L. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemp Clin Trials. 2023;135:107360. https://doi.org/10.1016/j.cct.2023.107360Opheim A, Gaulen Z, Solli KK, Latif ZE, Fadnes LT, Benth JŠ, Kunøe N, Tanum L. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. Am J Addict. 2021;30(5):453-60. https://doi.org/10.1111/ajad.13151Opheim A, Gaulen Z, Solli KK, Latif ZE, Fadnes LT, Benth JŠ, Kunøe N, Tanum L. Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. Am J Addict. 2021;30(5):453-60. https://doi.org/10.1111/ajad.13151Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54(2):127-35. https://doi.org/10.1016/s0376-8716(98)00152-5Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54(2):127-35. https://doi.org/10.1016/s0376-8716(98)00152-5Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997;14(1):19-22. https://doi.org/10.1016/s0740-5472(96)00164-xRoth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat. 1997;14(1):19-22. https://doi.org/10.1016/s0740-5472(96)00164-xRothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23(4):351-60. https://doi.org/10.1016/s0740-5472(02)00301-xRothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23(4):351-60. https://doi.org/10.1016/s0740-5472(02)00301-xSinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl). 2007;190(4):569-74. https://doi.org/10.1007/s00213-006-0640-8Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl). 2007;190(4):569-74. https://doi.org/10.1007/s00213-006-0640-8Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017;74(12):1197-205. https://doi.org/10.1001/jamapsychiatry.2017.3206Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017;74(12):1197-205. https://doi.org/10.1001/jamapsychiatry.2017.3206Volpicelli RG, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurology. 2006;1(4):389-98. https://doi.org/10.2217/14796708.1.4.389Volpicelli RG, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurology. 2006;1(4):389-98. https://doi.org/10.2217/14796708.1.4.389Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984;45(9 Pt 2):39-41Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984;45(9 Pt 2):39-41

The authors declare that there are no conflicts of interest present.